目的：探讨妊娠合并乙型肝炎患者血脂及雌激素水平检测的临床意义。方法：选择十堰市妇幼保键院收治的160例妊娠合并乙型肝炎孕妇作为观察组，选择同期无乙型肝炎的160例孕妇作为对照组，检测并比较两组的血脂水平及雌激素水平，分析影响妊娠合并乙型肝炎患者妊娠不良结局的危险因素。结果：血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）含量观察组均高于对照组，而高密度脂蛋白胆固醇（HDL-C）含量观察组明显低于对照组，差异均有统计学意义（P<0.05）。观察组与对照组的血清雌激素含量分别为（154.20±10.82）和（88.14±8.98）pmol·L^-1，两组差异有统计学意义（t=8.109，P<0.05）。观察组剖宫产、产后出血、胎儿窘迫、新生儿窒息、妊娠期高血压疾病等发生情况均明显高于对照组（P<0.05）。Logistic多元回归分析显示，LDL-C≥3.0 mmol·L^-1、雌激素≥100 pmol·L^-1、年龄≥35岁、乙肝病程≥2年是妊娠合并乙型肝炎患者妊娠不良结局的危险因素（P<0.05）。结论：妊娠合并乙型肝炎的患者伴随有血脂异常与雌激素高表达，可导致妊娠不良结局发生率增加，两者都可作为妊娠合并乙型肝炎预后的预测指标。

[1] 庄虔莹,刘敏,付冬,等.孕期服用替比夫定进行乙型肝炎母婴阻断的产后肝功能观察[J].中华实验和临床感染病杂志:电子版,2016,10(03):337-341.
[2] 王荣芋,张小楠,张占卿,等.肝组织内性甾体激素受体与慢性乙型肝炎肝组织病理状态的相关性[J].中华实验和临床感染病杂志:电子版,2015,17(1):19-26.
[3] 王习习,韩国荣,江红秀,等.慢性乙型肝炎病毒感染孕妇产后肝功能的变化[J].职业与健康,2016,32(4):498-501.
[4] 叶程,江金香,叶绿菊,等.妊娠合并乙型肝炎患者肝功能及血清HBV-DNA水平相关性研究[J].中国现代医生,2016,54(9):46-48.
[5] PAWOWSKA M,SOBOLEWSKA-PILARCZYK M.Recommendations for the management of prevention of vertical HBV and HCV infection[J].Przegl Epidemiol,2016,70(1):33-34.
[6] 赵书杰,李宛玲,吴祖辉,等.肝功能异常对乙型肝炎病毒感染孕妇母婴结局的影响[J].中华医院感染学杂志,2016,26(16):3794-3796.
[7] BURMESTER G R,LANDEWÉ R,GENOVESE M C,et al.Adalimumab long-term safety:infections,vaccination response and pregnancy outcomes in patients with rheumatoid arthritis[J].Ann Rheum Dis,2016,23(11):99-102.
[8] 赵雷,张玮.雌激素在慢性肝病发生发展中的作用研究现状[J].实用肝脏病杂志,2015,14(5):563-566.
[9] WANG L,WIENER J,BULTERYS M,et al.Hepatitis B viral load response to two antiviral regimens (Tenofovir/Lamivudine VS. Lamivudine) in HIV and HBV co-infected pregnant women in guangxi,china:The Tenofovir in Pregnancy(TIP)Study[J].J Infect Dis,2016,9(22):693-699.
[10] 黄蓓,万丽.妊娠合并乙型肝炎病毒感染的观察与护理[J].中国实用医药,2016,11(16):235-236.
[11] 罗浩,权志博.性激素与乙型病毒性肝炎相关性研究进展[J].现代检验医学杂志,2014,29(1):68-70.
[12] HUANG H,XU C,ZHOU X,et al.Incidence and seroprevalence of hepatitis E virus infection in pregnant women infected with hepatitis B virus and antibody placental transfer in infants[J].J Clin Virol,2016,9(82):84-88.
[13] TAN Z,YIN Y,ZHOU J,et al.Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission:outcomes of telbivudine treatment during pregnancy[J].Medicine (Baltimore),2016,95(40):4847-4852.
[14] NELSON N P,EASTERBROOK P J,MCMAHON B J.Epidemiology of hepatitis B virus infection and impact of vaccination on disease[J].Clin Liver Dis,2016,20(4):607-628.
[15] CAN Ö,GÖKÇE A M,CANBAKAN M,et al.Evaluation of pre-transplant panel reactive antibody levels and sensitization:a single-center study[J].Ann Transplant,2016,13(21):577-581.
[16] DESALEGN D M,ABAY S,TAYE B.The availability and functional status of focused antenatal care laboratory services at public health facilities in Addis Ababa,Ethiopia[J].BMC Res Notes,2016,9(1):403-409.
[17] CHANG C Y,AZIZ N,POONGKUNRAN M,et al.Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B[J].Am J Gastroenterol,2016,111(10):1410-1415.
[18] 董青青,祝新红,王雄虎,等.孕妇乙肝感染与妊娠期肝内胆汁淤积症的相关性[J].中国生育健康杂志,2016,27(4):344-346.
[19] AEBI-POPP K,KAHLERT C,RAUCH A,et al.Heterogeneity in testing practices for infections during pregnancy:national survey across Switzerland[J].Swiss Med Wkly,2016,7(11):146-151.
[20] JOURDAIN G,NGO-GIANG-HUONG N,CRESSEY T R,et al.Prevention of mother-to-child transmission of hepatitis B virus:a phase Ⅲ,placebo-controlled,double-blind,randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen[J].BMC Infect Dis,2016,9(16):393-398.
[21] HU Y,FENG Z,LIU J,et al.Virological determinants of spontaneous postpartum e antigen seroconversion and surface antigen seroclearance in pregnant women infected with hepatitis B virus[J].Arch Med Res,2016,47(3):207-213.